{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:11:57Z","timestamp":1762431117776},"reference-count":106,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Metabolism Res"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti\u2010diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short\u2010acting glucagon\u2010like peptide\u20101 receptor agonists exenatide and lixisenatide. Current treatment guidelines will be summarized and discussed. \u00a9 2016 The Authors. <jats:italic>Diabetes\/Metabolism Research and Reviews<\/jats:italic> Published by John Wiley &amp; Sons Ltd.<\/jats:p>","DOI":"10.1002\/dmrr.2775","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T15:19:08Z","timestamp":1453303148000},"page":"497-511","source":"Crossref","is-referenced-by-count":18,"title":["Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short\u2010acting and other glucagon\u2010like peptide\u20101 receptor agonists"],"prefix":"10.1002","volume":"32","author":[{"given":"Francesco","family":"Giorgino","sequence":"first","affiliation":[{"name":"Dipartimento dell'Emergenza e dei Trapianti di Organi, Sezione di Medicina Interna, Endocrinologia, Andrologia e Malattie Metaboliche Universit\u00e0 degli Studi di Bari Aldo Moro  Bari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo C.","family":"Bonadonna","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Clinica e Sperimentale, Divisione di Endocrinologia Universit\u00e0 degli Studi di Parma, and AOU di Parma  Parma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Gentile","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Clinica e Sperimentale Seconda Universit\u00e0 degli Studi di Napoli  Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Vettor","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina \u2013 DIMED, Clinica Medica 3 Universit\u00e0 di Padova  Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Pozzilli","sequence":"additional","affiliation":[{"name":"Department of Endocrinology &amp; Diabetes Universit\u00e0 Campus Bio\u2010Medico  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.733"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.3.8355"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1984"},{"key":"e_1_2_6_7_1","unstructured":"Sanofi\u2010Aventis.Lyxumia\u00ae (lixisenatide) Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002445\/WC500140401.pdf. Last accessed 10 October2014."},{"key":"e_1_2_6_8_1","unstructured":"AstraZenecaAB.Byetta\u00ae (exenatide) Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/000698\/WC500051845.pdf. Last accessed 10 October2014."},{"key":"e_1_2_6_9_1","unstructured":"Novo NordiskAS.Victoza\u00ae (liraglutide) Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/001026\/WC500050017.pdf. Last accessed 10 October2014."},{"key":"e_1_2_6_10_1","unstructured":"GlaxoSmithKline.Esperzan\u00ae (albiglutide) Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002735\/WC500165117.pdf. Last accessed 10 October2014."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61206-4"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9909645"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2013.04.001"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.06.003"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03020.x"},{"issue":"1","key":"e_1_2_6_17_1","first-page":"OP75","article-title":"Impact of baseline gastric emptying on effects of lixisenatide and liraglutide in type 2 diabetes mellitus as add\u2010on to insulin glargine","volume":"54","author":"Menge BA","year":"2014","journal-title":"Diabetologia"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.281.1.E155"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2462"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01618.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1586\/eem.12.82"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1518"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00992.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70214-6"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01365.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60976-4"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01364.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01366.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0474"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0009-4"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2009.175067"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12076"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2760"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2007.00272.x"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1214"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1166"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3028-4"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1042426"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2010.05.008"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.6.1902"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00686.x"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.881"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0632"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-2-201101180-00300"},{"issue":"1","key":"e_1_2_6_46_1","first-page":"107","article-title":"Advancing basal insulin glargine with prandial lixisenatide QD vs. insulin glulisine QD or TID in T2DM: the GetGoal\u2010Duo2 evidence\u2010based trial (NCT01768559)","volume":"64","author":"Rosenstock J","year":"2015","journal-title":"Diabetes"},{"issue":"1","key":"e_1_2_6_47_1","first-page":"S9","article-title":"Therapeutic efficacy of lixisenatide added to basal insulin is greater when FPG is well\u2010controlled","volume":"56","author":"Vidal J","year":"2013","journal-title":"Diabetologia"},{"issue":"1","key":"e_1_2_6_48_1","first-page":"1","article-title":"Benefits of a fixed\u2010ratio formulation of once\u2010daily insulin glargine\/lixisenatide (LixiLan) vs glargine in type 2 diabetes inadequately controlled on metformin","volume":"57","author":"Rosenstock J","year":"2014","journal-title":"Diabetologia"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12262"},{"key":"e_1_2_6_50_1","unstructured":"ClinicalTrials.gov.Study of liraglutide in individuals with type 2 diabetes using insulin. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01628445. Last updated 26 May2015."},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2709"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2014.07.007"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.09.037"},{"issue":"1","key":"e_1_2_6_55_1","first-page":"1","article-title":"Efficacy and safety of liraglutide vs placebo when added to basal insulin analogues in subjects with type 2 diabetes (LIRA\u2010ADD2BASAL): a randomised, placebo\u2010controlled trial","volume":"57","author":"Lahtela J","year":"2014","journal-title":"Diabetologia"},{"issue":"1","key":"e_1_2_6_56_1","article-title":"Lixisenatide is effective and well tolerated in patients with type 2 diabetes mellitus and renal impairment","volume":"57","author":"Hanefeld M","year":"2014","journal-title":"Diabetologia"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60406-0"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2081"},{"key":"e_1_2_6_59_1","unstructured":"Food and Drug Administration.Briefing document: Liraglutide injection 3 mg. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM413317.pdf. Last accessed 3 February2015."},{"issue":"1","key":"e_1_2_6_60_1","first-page":"1015","article-title":"The effect of liraglutide in heart rate variability assessed by power spectral analysis on 24\u2010h electrocardiographic recording in patients with type 2 diabetes [abstract]","volume":"63","author":"Hara K","year":"2014","journal-title":"Diabetes"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1461"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00256.x"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2011-1052"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.2.233"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8227(92)90156-L"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050617"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12131-1"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2414"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1671"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2375"},{"key":"e_1_2_6_71_1","unstructured":"ClinicalTrials.gov.Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (lixisenatide) (ELIXA). Available from: http:\/\/clinicaltrials.gov\/show\/NCT01147250. Last updated 10 March2015."},{"key":"e_1_2_6_72_1","unstructured":"ClinicalTrials.gov.Researching cardiovascular events with a weekly incretin in diabetes (REWIND). Available from: http:\/\/clinicaltrials.gov\/show\/NCT01394952. Last updated 8 September2014."},{"key":"e_1_2_6_73_1","unstructured":"ClinicalTrials.gov.Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results \u2010 a long term evaluation (LEADER\u00ae). Available from: http:\/\/clinicaltrials.gov\/show\/NCT01179048. Last updated 7 May 2015."},{"key":"e_1_2_6_74_1","unstructured":"ClinicalTrials.gov.Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01144338. Last updated 29 May2015."},{"issue":"1","key":"e_1_2_6_75_1","first-page":"1018","article-title":"Lixisenatide as add\u2010on treatment among patients with different B\u2010cell function levels as assessed by HOMA\u2010B index","volume":"63","author":"Bonadonna RC","year":"2014","journal-title":"Diabetes"},{"issue":"2","key":"e_1_2_6_76_1","first-page":"978","article-title":"Adjunctive lixisenatide treatment improves glycemic control in patients with T2DM irrespective of \u00df\u2010Cell function","volume":"63","author":"Yabe D","year":"2014","journal-title":"Diabetes"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0146-4"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2588"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12276"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-142"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0876"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.10.003"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0001"},{"key":"e_1_2_6_84_1","unstructured":"ClinicalTrials.gov.Efficacy and safety of lixisenatideversusinsulin glulisine on top of insulin glargine with or without metformin in type 2 diabetic patients (GetGoal Duo\u20102). Available from: https:\/\/clinicaltrials.gov\/show\/NCT01768559. Last updated 19 January2015."},{"key":"e_1_2_6_85_1","first-page":"CD006739","article-title":"Dipeptidyl peptidase\u20104 (DPP\u20104) inhibitors for type 2 diabetes mellitus","volume":"2","author":"Richter B","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_86_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.554532"},{"key":"e_1_2_6_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01586.x"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01540.x"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1727"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01603.x"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01606.x"},{"key":"e_1_2_6_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.04.013"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.2.194"},{"key":"e_1_2_6_94_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2191"},{"key":"e_1_2_6_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00914.x"},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0024-0"},{"key":"e_1_2_6_97_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-10-7"},{"key":"e_1_2_6_98_1","unstructured":"BoehringerIngelheim.Tradjenta\u00ae (linagliptin) Prescribing Information. http:\/\/bidocs.boehringer\u2010ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Tradjenta\/Tradjenta.pdf. Last accessed 20 January2015."},{"key":"e_1_2_6_99_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0931"},{"key":"e_1_2_6_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2411"},{"key":"e_1_2_6_101_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1523"},{"issue":"1","key":"e_1_2_6_102_1","first-page":"OR152","article-title":"Saxagliptin increases B\u2010cell function and improves HOMA index in patients with latent autoimmune diabetes in adults","volume":"63","author":"Pozzilli P","year":"2014","journal-title":"Diabetes"},{"key":"e_1_2_6_103_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3633"},{"key":"e_1_2_6_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0017"},{"key":"e_1_2_6_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385855-9.00003-5"},{"key":"e_1_2_6_106_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S317"},{"key":"e_1_2_6_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-011-0004-1"}],"container-title":["Diabetes\/Metabolism Research and Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdmrr.2775","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.2775","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dmrr.2775","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.2775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T21:25:53Z","timestamp":1696627553000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dmrr.2775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1002\/dmrr.2775"],"URL":"https:\/\/doi.org\/10.1002\/dmrr.2775","archive":["Portico"],"relation":{},"ISSN":["1520-7552","1520-7560"],"issn-type":[{"value":"1520-7552","type":"print"},{"value":"1520-7560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,30]]}}}